Significantly improved survival outcomes of wild-type BRCA patients with the Vigil vaccine (an autologous tumour cell vaccine which downregulates TGF-β) justify phase III assessments and potential future FDA approval [197,198,199]. This evidence concerns the gene TGFB1 and neoplasm.